| Company | Reason for receipt of fees | Total amount received |
|---|---|---|
| Sanofi | Analysing in 2003 the results of a study to examine by Sanofi to see if its recommended indications for use of irbesartan in diabetic albuminuria led to over-diagnosis or over-treatment | £2000 - £5000 |
| Company | Reason for receipt of fees | Total amount received |
|---|---|---|
| Applied Nanodetectors Ltd | Advice in 2013 about how to assess the diagnostic usefullness of their Nanaodetectors in order to predict the opitimum treatment of patients | £100- £1000 |
| Company | Reason for receipt of fees | Total amount received |
|---|---|---|
| Oxford University Press | Annual royalties from the Oxford Handbook of Clinical Diagnosis | £5000 - £10000 |